European Association for the Study of Diabetes

European Association for the Study of Diabetes Promoting excellence in diabetes care since 1965. The European Association for the Study of Diabetes e.V.

(EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. EASD is a networks for diabetologists with active members from all over the world. Membership is open to scientists, physicians, students, postdocs and fellows, allied health professionals and nurses who are interested in the field of diabetes or related dise

ases. The EASD Annual Meeting is one of the largest diabetes conferences in the world, attracting thousands of delegates each year. The scientific programme includes hundreds of talks, presentations and discussions on the latest results from basic and clinical diabetes research. EASD is also a leading player in postgraduate education having trained thousands of healthcare professionals through dedicated training courses and online education activities. Our award winning e-Learning platform, offers free access to courses developed with world-class experts in diabetes research and care. The Association is actively involved in producing and endorsing statements and guidelines translating the latest results from diabetes research into best practices in diabetes management. These statements and guidelines have proven to have significant visibility and substantial impact on health care, particularly when concerning statements on treatment and diagnostic criteria. By creating the Early Career Academy, EASD has increased its commitment to support, train, mentor, and create opportunities for scientists, clinicians, and students who are at an early or intermediate stage of their career. The European Foundation for the Study of Diabetes (EFSD) was founded by EASD in 2000 to stimulate diabetes research in Europe. EFSD offers support in all areas of diabetes research through a wide range of joint and stand-alone initiatives. Funding streams are available throughout the year and since inception, EFSD has committed over €120 million to diabetes research in Europe. EASD is also the publisher of Diabetologia, a major monthly international diabetes journal with an impact factor of 8.2 (2022). The journal publishes original clinical, translational and experimental research on all aspects of diabetes and related subjects. For more information about EASD, please visit: www.easd.org

⏰ 𝐅𝐢𝐧𝐚𝐥 𝐫𝐞𝐦𝐢𝐧𝐝𝐞𝐫: applications for the inaugural EASD AI Workshop are nearing their deadline soon. 📍“Artificial Intellig...
21/08/2026

⏰ 𝐅𝐢𝐧𝐚𝐥 𝐫𝐞𝐦𝐢𝐧𝐝𝐞𝐫: applications for the inaugural EASD AI Workshop are nearing their deadline soon.

📍“Artificial Intelligence in Diabetes Care: From Foundations to Clinical Practice” is EASD's first dedicated AI workshop, held before the start of in Milan on Sunday, 27 September 2026.

📅 Applications close: 26 August 2026 | 🕛 17:00 CEST

This is your last chance to apply for a half-day, interactive pre-conference workshop covering predictive, generative and agentic AI, AI-powered diabetes technology, responsible AI and hands-on prompting exercises (No previous AI or programming experience required).

👉 Learn more and send your complete application: https://www.easd.org/education/meetings-and-courses/ai-workshop-2026/

📻 As we count down to  , we're revisiting some of our favourite EASD Live conversations straight from our archives!This ...
21/08/2026

📻 As we count down to , we're revisiting some of our favourite EASD Live conversations straight from our archives!

This one: "Targeting mitochondria to treat diabetes and heart disease" from Prof. Gerald I. Shulman (Yale School of Medicine), 11th recipient of the EASD - Novo Nordisk Foundation Diabetes Prize for Excellence, talked us through four decades of research into mitochondria, insulin resistance, and where the field is heading next.

📺 Watch: https://www.youtube.com/watch?v=CEb9gPAkIcI&t=1s

🎧 Listen: https://diabetes-insights.podigee.io/33-mitochondria-insulin-resistance-and-the-future-of-diabetes-treatment-with-prof-jerry-shulman

📢 LAST CALL!!!! Applications Closing Soon! The   and   European Diabetes Research Programme is still accepting applicati...
20/08/2026

📢 LAST CALL!!!! Applications Closing Soon! The and European Diabetes Research Programme is still accepting applications.

This programme supports innovative basic and clinical diabetes research in Europe, with funding to support their innovative basic or clinical diabetes research.

📅 Application deadline: 1 September 2026 | 🕛12:00 hrs CEST

🔗 Learn more and apply now via the EFSD Programme Portal 👉 https://www.europeandiabetesfoundation.org/programmes/programme-calls/efsd-lilly-european-diabetes-research-programme/

Programme supported by Lilly Diabetes International.

📢 🎤 𝐒𝐏𝐄𝐀𝐊𝐄𝐑 𝐇𝐈𝐆𝐇𝐋𝐈𝐆𝐇𝐓: Everything on Metabolically Healthy Obesity: Fact or Fiction?Join Prof. Ruth Loos (Novo Nordisk F...
20/08/2026

📢 🎤 𝐒𝐏𝐄𝐀𝐊𝐄𝐑 𝐇𝐈𝐆𝐇𝐋𝐈𝐆𝐇𝐓: Everything on Metabolically Healthy Obesity: Fact or Fiction?

Join Prof. Ruth Loos (Novo Nordisk Foundation Center for Basic Metabolic Research) at the EASD 2026 Annual Meeting in Milan for her presentation titled: 🧬 "Genetic evidence for or against metabolically healthy obesity"

📅 Tuesday, 29 September 2026 | 🕒 17:25 - 17:45 hrs CEST |📍 London Hall

Mark your calendar and spread the word 👉 https://cattendee.abstractsonline.com/meeting/21509/session/18

Expect expert insights, practical relevance, and a session you won't want to miss.

19/08/2026

⚡ All you need to know from the long-awaited updated ADA EASD consensus report on the management of type 1 diabetes in adults:

👉 In a new Diabetes Perspectives episode, Professor Kirsten Nørgaard and Dr Hans De Vries from the report’s writing group discuss what they believe will matter most in day-to-day clinical practice. They examine these questions and more:

✅ Are CGM and AID for everyone living with type 1 diabetes?
✅ Should low-risk patients still undergo annual retinopathy screening?
✅ Are GLP-1 receptor agonists and other adjunctive therapies ready for wider use in type 1 diabetes?
✅ How aggressively should cardiovascular risk factors be treated?
✅ When are individualised targets needed?

📺 Watch this new episode on the EASD e-Learning platform: https://easd-elearning.eu/episode/371/Decoding-the-updated-ADA-EASD-consensus-report-on-the-management-of-type-1-diabetes.html

🧠 Meet Dr. Daniel Coral (Lund University), recipient of the   and   European Diabetes Research Programme. His project, “...
18/08/2026

🧠 Meet Dr. Daniel Coral (Lund University), recipient of the and European Diabetes Research Programme. His project, “Modelling of eGFR trajectories to dissect CKD heterogeneity and response to treatment,” uses longitudinal kidney-function data to identify distinct patterns of renal decline following type 2 diabetes diagnosis.

🗣️ Reflecting on the programme, Dr. Coral shares:
“The EFSD and Lilly award provided the research time, infrastructure and international collaboration needed to develop and externally validate this work. It strengthened my expertise in longitudinal precision medicine and helped me establish an independent research direction focused on dynamic disease trajectories and personalised risk stratification.”

🤝 We love seeing where -supported research can lead and the collaborations it helps build. Dr. Coral’s work brings together an international research team, including Dr. Jennifer Sargent, Editor-in-Chief of Metabologia, alongside colleagues contributing to this work on longitudinal precision medicine.

📖 Read more: https://www.nature.com/articles/s41591-026-04309-6

📅 This programme is still open until 1 September 2026 | 🕛 12:00 midday (CEST)

🔗👉 Learn more and apply now: https://www.europeandiabetesfoundation.org/programmes/programme-calls/efsd-lilly-european-diabetes-research-programme/

Generously supported by Lilly Diabetes International.

⏰ Reminder: The call is officially open for the EASD Guideline Development Panel (GDP) on the Management of Diabetes in ...
17/08/2026

⏰ Reminder: The call is officially open for the EASD Guideline Development Panel (GDP) on the Management of Diabetes in Older Adults.

This panel will help shape clinical guidance for one of the most complex and fast-growing areas of diabetes care. 🩺 We're looking for clinicians, researchers and other experts with relevant experience in this field to contribute their knowledge and perspective. we want to hear from you 🫵

📅 Deadline: 31 August 2026

🔗👉 Learn more and apply here: https://www.easd.org/guidelines/statements-guidelines/management-of-diabetes-in-older-adults/

🎉 Fantastic!!!! What an Incredible milestone for the 5K EASD Challenge: 7,000+ registered, 450+ finishers, 130 countries...
14/08/2026

🎉 Fantastic!!!! What an Incredible milestone for the 5K EASD Challenge: 7,000+ registered, 450+ finishers, 130 countries and counting.

💙 Still time to join the global movement for in Milan 🇮🇹

Learn more 👉 https://www.easd5k.com/

🎙️🔙 𝐓𝐡𝐫𝐨𝐰𝐛𝐚𝐜𝐤 𝐭𝐨 𝐨𝐧𝐞 𝐨𝐟 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫'𝐬 𝐡𝐨𝐭𝐭𝐞𝐬𝐭 𝐭𝐫𝐢𝐚𝐥 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧𝐬: CVOT: comparing tirzepatide and dulaglutide on major adve...
14/08/2026

🎙️🔙 𝐓𝐡𝐫𝐨𝐰𝐛𝐚𝐜𝐤 𝐭𝐨 𝐨𝐧𝐞 𝐨𝐟 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫'𝐬 𝐡𝐨𝐭𝐭𝐞𝐬𝐭 𝐭𝐫𝐢𝐚𝐥 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧𝐬: CVOT: comparing tirzepatide and dulaglutide on major adverse cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease.

If you missed this conversation the first-time round, now's your chance to catch up 👇

🎉 And good news - SURPASS-CVOT is coming back to the big stage ! Join us in Milan:
📅 Wednesday, 30 September 2026 | 🕗 08:30 – 09:30 |📍 Dublin Hall

🎧 Listen to last year's discussion here: https://diabetes-insights.podigee.io/47-surpass-cvot-a-comparison-of-tirzepatide-and-dulaglutide

📖 Explore the full programme here: https://www.easd.org/annual-meeting/easd-2026/programme/

Adresse

EASD/Rheindorfer Weg 3
Düsseldorf
40591

Öffnungszeiten

Montag 08:00 - 17:00
Dienstag 08:00 - 17:00
Mittwoch 08:00 - 17:00
Donnerstag 08:00 - 17:00
Freitag 08:00 - 17:00

Telefon

+492117584690

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Association for the Study of Diabetes erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Organisation Kontaktieren

Nachricht an European Association for the Study of Diabetes senden:

Verknüpfungen

Teilen